| Document |
Document Title |
|
JP6158513B2 |
A paclitaxel/steroid complex comprising paclitaxel and steroid is disclosed. The molar ratio of paclitaxel to steroid is 1:0.2~4, preferably 1:0.25~2. A process for the preparation thereof and the use thereof in the manufacture of submic...
|
|
JP6153597B2 |
Compounds of the formula in which the substituents are as defined in claim 1, are suitable for use as nematicides.
|
|
JP2017513850A |
The present disclosure describes compounds of formula (I) (in formula, ring A, ring B, R, R).2, R3, N, and p are as defined herein) and their pharmaceutically acceptable salts, which are active as modulators of the retinoid-related orpha...
|
|
JP6106634B2 |
The present invention relates to new taxane analogs useful for the treatment of cancer as well as methods for producing the same. The chemical compounds according to the present invention have the general Formula (I) wherein R 1 and R 2 ...
|
|
JP6105489B2 |
Disclosed are an aryl glycoside compound as represented by formula I or formular I', a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said ary...
|
|
JP6097405B2 |
The present invention relates to a novel method for preparing cabazitaxel from 10-deacetylbaccatin III, and a novel intermediate therefor, and more specifically, to: a method which allows cabazitaxel to be more easily prepared in a high ...
|
|
JP6087381B2 |
The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with ...
|
|
JP2017039725A |
To provide methods of treating a cancer.Methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprise administering a compound represented by formula I. A method for inhibiting a mutant IDH1 activity comp...
|
|
JP2017036250A |
To provide a method for producing an ester compound that shortens the reaction time for the esterification of an imidate compound without generating toxic gas.The present invention provides a method for producing an ester compound repres...
|
|
JP6081354B2 |
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.
|
|
JP6068487B2 |
Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and com...
|
|
JP6051313B2 |
The present invention discloses the device and method for continuously preparing high-purity AKD without solvent. The adopted device includes a kind of reactor which could make continuous mixing reaction of raw materials. The main prepar...
|
|
JP6048406B2 |
The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
|
JP6039194B2 |
The present invention provides a salt represented by the formula (I): wherein Q1 and Q2 independently each represent a fluorine atom or a C1-C6 perfluoroalkyl group, L1 represents a C1-C17 divalent saturated hydrocarbon group in which on...
|
|
JP6034026B2 |
A resist composition contains (A1) a resin having a structural unit represented by the formula (I), (A2) a resin being insoluble or poorly soluble in alkali aqueous solution, but becoming soluble in an alkali aqueous solution by the acti...
|
|
JP6030752B2 |
This invention relates to methods for making oxetan-3-ylmethanamines having the formula (I) wherein R1? and R2? are as defined herein. The methods of the invention provide the compounds of formula (I) in high yields and under conditions ...
|
|
JP2016193439A |
To provide a catalyst for catalytic carbonylation and a method.The invention relates to a field of catalytic carbonylation of heterocycles, and more specifically to a unimolecular catalyst, and a related method for carbonylating an epoxi...
|
|
JP6025861B2 |
The present invention relates to a novel crystalline ethyl acetate solvate form of cabazitaxel or 4α-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β-hydroxy-7β,10β
-dimethoxy-9-oxo-11-taxen-13α-yl(2R,3S)-3-tert-butoxycarbon
ylamino-2-hydroxy...
|
|
JP2016534066A |
The present invention relates to the new crystal form voice of Caba Gita cheating on the fare of formula (I). Especially the present invention is form S2 (solvent Japanese food by 2* methyl tetrahydro franc), Four new crystalline solvent...
|
|
JP2016534065A |
The present invention relates to the new anhydrate crystal form voice of Caba Gita cheating on the fare of formula (I) named form H. The further object of the present invention is decanoyl. Triglyceride and octanoyl The mixture of trigly...
|
|
JP2016529238A |
The present invention relates to a compound of formula (I). [Chemical 1]Provided are a method for producing a compound of the present invention and a therapeutic use thereof. The present invention further provides a combination of a phar...
|
|
JP5991327B2 |
Provided are: an organic electronic material which can be easily multilayered and that can be used in substrates, such as resin, that cannot be processed at high temperatures; an ink composition containing the same; an organic thin film ...
|
|
JP5989987B2 |
|
|
JP5986108B2 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1, A2 and n are as described herein, compositions including the compounds and methods of using the compounds.
|
|
JP5976011B2 |
Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. ...
|
|
JP5962949B2 |
|
|
JP5937001B2 |
The present application provides a method for producing an beta-lactone product. The method includes the steps of: reacting an epoxide, a solvent with a carbonylation catalyst and carbon monoxide to produce a reaction stream comprising a...
|
|
JP2016517412A |
The present invention relates to the compound for FASN prevention, constituents, those composition, application, and an antidote. An example of the compound of the present invention is shown below. [Drawing 1]
|
|
JP5935328B2 |
|
|
JP5932219B2 |
Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C and dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7b...
|
|
JP5928737B2 |
The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
|
JP5911989B2 |
A method for preparing highly pure anhydrous crystalline docetaxel is provided. The method for preparing highly pure anhydrous crystalline docetaxel enables preparation of anhydrous crystalline docetaxel that has purity of 99.5% or more,...
|
|
JP5905882B2 |
The invention relates to a method for the production of L-carnitine, wherein a chiral ²-lactone carnitine precursor is obtained by a [2+2] cycloaddition of ketene with an aldehyde X-CH 2 -CHO, wherein X is selected from Cl, Br, I and tr...
|
|
JP5893558B2 |
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
|
|
JP5884005B2 |
The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with ...
|
|
JP5875678B2 |
The present invention involves a compound represented by general formula (I), a derivative thereof and a use thereof: wherein R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , R 5c and X are defined as in the description.
|
|
JP2016505587A |
The present invention isWith respect to the novel compounds (in the formula, the variable elements have the meanings set forth in the claims in free and salt form) and, as appropriate, their enantiomers and geometric isomers. The compoun...
|
|
JP5870197B2 |
There is provided a method for preparing docetaxel that is a taxane derivative, and more specifically, a method for preparing docetaxel in which since the docetaxel having high purity can be prepared at a high yield through a simple prod...
|
|
JP5859000B2 |
In order to produce an intermediate from which a cyclic alcohol compound can be stereoselectively obtained, a method for producing an oxetane compound according to the present invention includes the step of reacting, with a cyanide salt,...
|
|
JP5851282B2 |
|
|
JP5851998B2 |
|
|
JP5847088B2 |
The present invention relates to compounds of the formula I, wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endo...
|
|
JP5843658B2 |
|
|
JP5843659B2 |
|
|
JP5841295B2 |
Process for the production of a chemical compound from a carbon dioxide starting material, comprising the steps of a) providing a feed stream consisting mainly of carbon dioxide; b) electrolyzing in an electrolysis stage the carbon dioxi...
|
|
JP2016500368A |
The present invention has been substituted 1- (arylethynyl)-, 1- (heteroarylethynyl)-, 1- (to increase stress tolerance and / or increase plant yield in plants for abiotic stress. Heterocyclic ethynyl)-and 1- (cycloalkenylethynyl) cycloh...
|
|
JP5834489B2 |
|
|
JPWO2013146651A1 |
To provide a method for industrially producing a cyclic ether group-containing (meth) acrylate in a high yield, and to provide an active energy ray-curable resin composition obtained by blending a cyclic ether group-containing (meth) acr...
|
|
JP2015533782A |
It is an inhibitor of HBV replication of formula (I) and contains its steric chemical isomers, as well as salts, hydrates and solvates, in formulas B, R.1, R2And R4Has the meaning as defined herein. The present invention also relates to ...
|
|
JP5806532B2 |
|
